BIOCRATES Life Sciences AG, a global leader in metabolomics, announced today the introduction of MxP(R) Quant 500. This new, comprehensive analytical method enables the quantitative measurement of a large number of different metabolites produced by intestinal bacteria. MxP(R) Quant 500 will provide researchers with new insights into the highly interesting interaction between the body and the intestinal bacteria known as the microbiome.
The metabolite profiles obtained with MxP(R) Quant 500 can be correlated with different diseases and provide new information on which metabolic pathways are important in the manifestation and progression of cancer, diabetes and neurological diseases such as Parkinson’s or Alzheimer’s disease.
“Intestinal bacteria have a great influence on human health and well-being. However, their function is still barely understood. The genomic identification of intestinal bacteria is not sufficient to understand their effect in our body,” commented Dr. Wulf Fischer-Knuppertz, CEO of BIOCRATES. “The bacteria in the digestive tract produce a large number of substances that are absorbed by the body and have a variety of effects.”
